CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 140 enrolled
Drug / intervention
B244 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03590366
NCT03590366Phase 2Completed
CompareCT.gov

A Vehicle-Controlled, Double-Blind, Randomized Phase II Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Mild to Moderate Rosacea

AOBiome LLC·interventional·Posted Jul 18, 2018·Updated Sep 16, 2022

In Brief

A Phase 2 clinical trial evaluating B244 and Vehicle for Rosacea. Completed, enrolled 140 participants across 9 sites.

Detailed Summary

This is a Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized Phase II trial, comparing the effect of twice daily B244 application for 8 weeks vs. vehicle application on treatment of mild to moderate rosacea.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRosacea
CountriesUnited States
CollaboratorsbioRASI, LLC

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJul 18, 2018
Enrollment StartJul 2, 2018
Primary CompletionFeb 11, 2019
Study CompletionMar 5, 2019
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 8.0 years ago

Interventions

B244biological

B244 Suspension

Vehiclebiological

Vehicle suspension